DE60335672D1 - Verfahren zur reinigung von adenovirus - Google Patents

Verfahren zur reinigung von adenovirus

Info

Publication number
DE60335672D1
DE60335672D1 DE60335672T DE60335672T DE60335672D1 DE 60335672 D1 DE60335672 D1 DE 60335672D1 DE 60335672 T DE60335672 T DE 60335672T DE 60335672 T DE60335672 T DE 60335672T DE 60335672 D1 DE60335672 D1 DE 60335672D1
Authority
DE
Germany
Prior art keywords
virus
adenovirus
cleaning
particles
levels
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60335672T
Other languages
English (en)
Inventor
John O Konz Jr
Ann Lee
Aaron Goerke
Chi Shung Brian To
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29549953&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60335672(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme LLC
Application granted granted Critical
Publication of DE60335672D1 publication Critical patent/DE60335672D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
DE60335672T 2002-05-14 2003-05-13 Verfahren zur reinigung von adenovirus Expired - Lifetime DE60335672D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38033202P 2002-05-14 2002-05-14

Publications (1)

Publication Number Publication Date
DE60335672D1 true DE60335672D1 (de) 2011-02-17

Family

ID=29549953

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60335672T Expired - Lifetime DE60335672D1 (de) 2002-05-14 2003-05-13 Verfahren zur reinigung von adenovirus
DE60313451T Expired - Lifetime DE60313451T2 (de) 2002-05-14 2003-05-13 Verfahren zur reinigung von adenovirus

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60313451T Expired - Lifetime DE60313451T2 (de) 2002-05-14 2003-05-13 Verfahren zur reinigung von adenovirus

Country Status (9)

Country Link
US (3) US20050196854A1 (de)
EP (2) EP1506287B1 (de)
AT (2) ATE360683T1 (de)
AU (1) AU2003229060A1 (de)
DE (2) DE60335672D1 (de)
DK (1) DK1506287T3 (de)
ES (2) ES2357366T3 (de)
PT (1) PT1506287E (de)
WO (1) WO2003097797A2 (de)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003229060A1 (en) * 2002-05-14 2003-12-02 Merck And Co., Inc. Methods of adenovirus purification
US20070207461A1 (en) * 2004-02-23 2007-09-06 Crucell Holland B.V. Virus Purification Methods
JP2008501339A (ja) * 2004-06-01 2008-01-24 ジェンザイム・コーポレイション Ａａｖベクターの凝集を防ぐための組成物およびその方法
JP2008518632A (ja) * 2004-11-03 2008-06-05 イントロゲン セラピューティックス， インコーポレイテッド アデノウイルスベクターの製造および精製のための新規方法
EP1851343A2 (de) * 2005-02-11 2007-11-07 Merck and Co., Inc. Adenovirus serotyp 26-vektoren, nukleinsäure und auf diese weise erzeugte viren
CN101155915B (zh) * 2005-04-11 2013-12-04 克鲁塞尔荷兰公司 利用超滤进行病毒纯化
US7673757B2 (en) 2006-02-17 2010-03-09 Millipore Corporation Adsorbent filter media for removal of biological contaminants in process liquids
WO2007123961A2 (en) * 2006-04-20 2007-11-01 Wyeth Purification processes for isolating purified vesicular stomatitis virus from cell culture
EP2173861B2 (de) * 2007-06-15 2017-02-22 Amgen Inc. Verfahren zur behandlung von zellkulturmedien für die verwendung in einem bioreaktor
EP2307551B1 (de) 2008-06-18 2016-12-14 Oxford BioMedica (UK) Limited Aufreinigung retroviraler vektoren
CN102203242B (zh) * 2008-11-03 2013-06-12 克鲁塞尔荷兰公司 产生腺病毒载体的方法
JP2010207800A (ja) * 2009-02-16 2010-09-24 Kuraray Co Ltd ろ過ユニットおよびこれを備えたろ過装置
US8460920B2 (en) * 2009-10-15 2013-06-11 Crucell Holland B.V. Method for the purification of adenovirus particles
ES2445713T3 (es) * 2009-10-15 2014-03-04 Crucell Holland B.V. Proceso para la purificación de adenovirus a partir de cultivos de alta densidad celular
CN102762721B (zh) 2010-02-15 2015-03-11 克鲁塞尔荷兰公司 用于生产Ad26腺病毒载体的方法
SG184833A1 (en) 2010-04-14 2012-11-29 Emd Millipore Corp Methods of producing high titer, high purity virus stocks and methods of use thereof
CA2802430C (en) 2010-07-20 2021-07-20 Bavarian Nordic A/S Method for harvesting poxvirus
TWI503411B (zh) 2010-08-11 2015-10-11 Nat Health Research Institutes Ｂ群腦膜炎球菌次單位疫苗之製造及純化
DE102010046817A1 (de) * 2010-09-28 2012-03-29 Sartorius Stedim Biotech Gmbh Verfahren zur Abtrennung von Viren aus einem Kontaminanten enthaltenden flüssigen Medium
CA2864956C (en) 2012-03-12 2021-11-09 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
JP5845376B2 (ja) 2012-03-22 2016-01-20 クルセル ホランド ベー ヴェー Ｒｓｖに対するワクチン
US9119813B2 (en) 2012-03-22 2015-09-01 Crucell Holland B.V. Vaccine against RSV
EP2984467B1 (de) * 2012-10-18 2020-10-14 Innovaprep LLC Flüssig-in-flüssig-biopartikel-fraktionierung und -konzentrierung
WO2014174018A1 (en) 2013-04-25 2014-10-30 Crucell Holland B.V. Stabilized soluble prefusion rsv f polypeptides
CA2914792C (en) 2013-06-17 2024-02-27 Crucell Holland B.V. Stabilized soluble pre-fusion rsv f polypeptides
US10072250B2 (en) * 2013-07-11 2018-09-11 Takara Bio Inc. Method for manufacturing non-enveloped virus
US20160228825A1 (en) * 2013-10-07 2016-08-11 Novartis Ag Treated filter
US20150225713A1 (en) * 2014-02-10 2015-08-13 Zymo Research Corporation Methods for nucleic acid capture
WO2015191508A1 (en) 2014-06-09 2015-12-17 Voyager Therapeutics, Inc. Chimeric capsids
US10023846B2 (en) 2014-07-10 2018-07-17 Takara Bio Inc. Production method for non-enveloped virus particles
WO2016012445A2 (en) 2014-07-24 2016-01-28 Crucell Holland B.V. Process for the purification of poliovirus from cell cultures
CA2966620A1 (en) 2014-11-05 2016-05-12 Voyager Therapeutics, Inc. Aadc polynucleotides for the treatment of parkinson's disease
CN114717264A (zh) 2014-11-14 2022-07-08 沃雅戈治疗公司 治疗肌萎缩性侧索硬化(als)的组合物和方法
CN112375760A (zh) 2014-11-14 2021-02-19 沃雅戈治疗公司 调节性多核苷酸
EP3230441A4 (de) 2014-12-12 2018-10-03 Voyager Therapeutics, Inc. Zusammensetzungen und verfahren zur herstellung von scaav
EP3243904A4 (de) * 2015-01-09 2018-06-27 Takara Bio Inc. Verfahren zur herstellung von unbehüllten viruspartikeln
US9862936B2 (en) 2015-01-13 2018-01-09 Alfa Wassermann, Inc. Methods of purifying adeno-associated virus (AAV) and/or recombinant adeno-associated virus (rAAV) and gradients and flow-through buffers therefore
EP3054007A1 (de) 2015-02-09 2016-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Reinigung von rekombinanten, adeno-assoziierten viren mit einem immunaffinen reinigungsschritt
EP3054006A1 (de) 2015-02-09 2016-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Reinigung von rekombinanten adeno-assoziierten viruspartikeln mittels mehrstufiger anionischer austauschchromatografie
PL3283634T3 (pl) 2015-04-14 2019-10-31 Janssen Vaccines & Prevention Bv Rekombinowany adenowirus eksprymujący dwa transgeny z dwukierunkowym promotorem
CA2991002C (en) 2015-07-07 2023-11-28 Janssen Vaccines & Prevention B.V. Vaccine against rsv
EA035909B1 (ru) 2015-07-07 2020-08-31 Янссен Вэксинс Энд Превеншн Б.В. Стабилизированные растворимые f-полипептиды rsv до слияния
US20180230489A1 (en) 2015-10-28 2018-08-16 Voyager Therapeutics, Inc. Regulatable expression using adeno-associated virus (aav)
ES2858315T3 (es) 2016-04-05 2021-09-30 Janssen Vaccines & Prevention Bv Proteína F de prefusión de VRS soluble estabilizada para uso en la profilaxis de la infección por VRS
BR112018070323A2 (pt) 2016-04-05 2019-01-29 Janssen Vaccines & Prevention Bv vacina contra rsv
EP3448874A4 (de) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. Zusammensetzungen zur behandlung einer erkrankung
WO2017189964A2 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
MX2018013817A (es) 2016-05-12 2019-03-21 Janssen Vaccines & Prevention Bv Promotor bidireccional potente y equilibrado.
EP3458588A4 (de) 2016-05-18 2020-01-15 Voyager Therapeutics, Inc. Modulatorische polynukleotide
BR112018073472A2 (pt) 2016-05-18 2019-08-27 Voyager Therapeutics Inc composições e métodos de tratamento da doença de huntington
IL264119B2 (en) 2016-05-30 2023-04-01 Janssen Vaccines Prevention B V f proteins of rsv are stabilized before fusion
WO2017220499A1 (en) 2016-06-20 2017-12-28 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
EP3484506A1 (de) 2016-07-14 2019-05-22 Janssen Vaccines & Prevention B.V. Hpv-impfstoffe
US11298041B2 (en) 2016-08-30 2022-04-12 The Regents Of The University Of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
BR112019009033A2 (pt) * 2016-11-04 2019-07-09 Baxalta GmbH métodos de purificação de vírus adenoassociado
CN108085301B (zh) * 2016-11-22 2021-10-26 贺道耀 从宿主细胞提取和纯化腺相关病毒和腺病毒的方法及其组分和试剂盒
US10294452B2 (en) 2016-11-22 2019-05-21 Dao-Yao He Lysis, extraction and purification of adeno-associated virus and adenovirus from host cells
BR112019015671A2 (pt) 2017-02-09 2020-04-14 Janssen Vaccines & Prevention Bv promotor potente e curto para expressão de genes heterológicos
AU2018261790A1 (en) 2017-05-05 2019-11-28 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
JP2020518259A (ja) 2017-05-05 2020-06-25 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ハンチントン病治療組成物および方法
CA3061278A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
CN111132626B (zh) 2017-07-17 2024-01-30 沃雅戈治疗公司 轨迹阵列引导系统
JP7221275B2 (ja) 2017-08-03 2023-02-13 ボイジャー セラピューティクス インコーポレイテッド Ａａｖを送達するための組成物および方法
US11229695B2 (en) 2017-09-15 2022-01-25 Janssen Vaccines & Prevention B.V. Method for the safe induction of immunity against RSV
US20200237799A1 (en) 2017-10-16 2020-07-30 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
US11434502B2 (en) 2017-10-16 2022-09-06 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (ALS)
US20210010028A1 (en) 2018-03-06 2021-01-14 Voyager Therapeutics, Inc. Insect cell manufactured partial self-complementary aav genomes
JP7048889B2 (ja) * 2018-04-16 2022-04-06 日本電信電話株式会社 バクテリア産生セルロースカーボンの製造方法
US20210047626A1 (en) 2018-04-24 2021-02-18 Merck Sharp & Dohme Corp. Scalable chromatography process for purification of human cytomegalovirus
WO2019212921A1 (en) * 2018-04-29 2019-11-07 Regenxbio Inc. Scalable clarification process for recombinant aav production
JP2021523724A (ja) 2018-05-15 2021-09-09 フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド フソソーム組成物およびその使用
WO2019222441A1 (en) 2018-05-16 2019-11-21 Voyager Therapeutics, Inc. Aav serotypes for brain specific payload delivery
US20210214749A1 (en) 2018-05-16 2021-07-15 Voyager Therapeutics, Inc. Directed evolution
CA3103963A1 (en) 2018-07-02 2020-01-09 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord
US20210355454A1 (en) 2018-07-24 2021-11-18 Voyager Therapeutics, Inc. Systems and methods for producing gene therapy formulations
WO2020072849A1 (en) 2018-10-04 2020-04-09 Voyager Therapeutics, Inc. Methods for measuring the titer and potency of viral vector particles
AU2019380517A1 (en) 2018-11-14 2021-06-03 Flagship Pioneering Innovations V, Inc. Fusosome compositions for hematopoietic stem cell delivery
WO2020102499A2 (en) 2018-11-14 2020-05-22 Flagship Pioneering Innovations V, Inc. Fusosome compositions for cns delivery
AU2019378883A1 (en) 2018-11-14 2021-06-03 Flagship Pioneering Innovations V, Inc. Fusosome compositions for T cell delivery
JP2022522995A (ja) 2019-01-18 2022-04-21 ボイジャー セラピューティクス インコーポレイテッド Ａａｖ粒子を生成するための方法及びシステム
US20220243225A1 (en) 2019-04-29 2022-08-04 Voyager Therapeutics, Inc. SYSTEMS AND METHODS FOR PRODUCING BACULOVIRAL INFECTED INSECT CELLS (BIICs) IN BIOREACTORS
GB201909081D0 (en) * 2019-06-25 2019-08-07 Psioxus Therapeutics Ltd Method
US20220290182A1 (en) 2019-08-09 2022-09-15 Voyager Therapeutics, Inc. Cell culture medium for use in producing gene therapy products in bioreactors
US20220364114A1 (en) 2019-08-26 2022-11-17 Voyager Therapeutics, Inc. Controlled expression of viral proteins
CN111394390A (zh) * 2020-03-26 2020-07-10 赛诺（深圳）生物医药研究有限公司 用于新型冠状病毒基因疫苗的批量生产重组腺病毒的方法
EP3919613A1 (de) 2020-06-05 2021-12-08 Bia Separations D.O.O. Verbesserte reinigung von adeno-assoziiertem virus um kontaminierende dna effektiver zu entfernen
US20230295656A1 (en) 2020-08-06 2023-09-21 Voyager Therapeutics, Inc. Cell culture medium for use in producing gene therapy products in bioreactors
RU2745307C1 (ru) * 2020-12-01 2021-03-23 федеральное государственное бюджетное учреждение «Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи» Министерства здравоохранения Российской Федерации Способ очистки рекомбинантного аденовируса 26 серотипа (Ad26)
EP4255503A2 (de) * 2020-12-04 2023-10-11 Gritstone bio, Inc. Zusammensetzungen und verfahren zur verwendung davon
CA3205584A1 (en) * 2020-12-21 2022-06-30 Pfizer Inc. Methods and compositions for inhibiting excess nucleic acid precipitation
WO2022187548A1 (en) 2021-03-03 2022-09-09 Voyager Therapeutics, Inc. Controlled expression of viral proteins
TW202246516A (zh) 2021-03-03 2022-12-01 美商航海家醫療公司 病毒蛋白之控制表現
GB202117844D0 (en) 2021-12-09 2022-01-26 Oxford Biomedica Ltd Purification method
WO2024054983A1 (en) 2022-09-08 2024-03-14 Voyager Therapeutics, Inc. Controlled expression of viral proteins
CN115747017B (zh) * 2022-10-25 2023-06-09 上海华新生物高技术有限公司 一种腺病毒纯化装置

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4064232A (en) * 1974-01-14 1977-12-20 Sandoz Ltd. Process for isolating the immunogenic components of influenza viruses
US5837520A (en) * 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
WO1997032010A1 (fr) * 1996-02-29 1997-09-04 Takara Shuzo Co., Ltd. Procede pour la purification et l'elimination de virus
CA2272820C (en) 1996-11-20 2012-09-11 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
US6261823B1 (en) * 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
EP1200622A4 (de) 1999-07-06 2004-12-22 Merck & Co Inc Hiv impfstoff aus einem das gag-gen tragenden adenovirus
CA2399321C (en) 2000-03-07 2013-04-30 Robert K. Evans Adenovirus formulations
US6884613B2 (en) * 2000-08-25 2005-04-26 The General Hospital Corporation Selective precipitation of viruses
EP1320621A4 (de) 2000-09-15 2005-11-23 Merck & Co Inc Verbesserte adenovirale vakzine der ersten generation zur expression codon-optimierten hiv1-gag, pol, nef und modifikationen(25.03.02)
AU2003229060A1 (en) * 2002-05-14 2003-12-02 Merck And Co., Inc. Methods of adenovirus purification

Also Published As

Publication number Publication date
EP1506287B1 (de) 2007-04-25
EP1506287A4 (de) 2005-06-08
DK1506287T3 (da) 2007-08-20
WO2003097797A3 (en) 2004-02-19
US7326555B2 (en) 2008-02-05
ATE494362T1 (de) 2011-01-15
AU2003229060A8 (en) 2003-12-02
DE60313451T2 (de) 2008-01-03
US20080118970A1 (en) 2008-05-22
PT1506287E (pt) 2007-07-17
US20050196854A1 (en) 2005-09-08
EP1783212A1 (de) 2007-05-09
WO2003097797A2 (en) 2003-11-27
US20050153420A1 (en) 2005-07-14
EP1506287A2 (de) 2005-02-16
ATE360683T1 (de) 2007-05-15
EP1783212B1 (de) 2011-01-05
ES2357366T3 (es) 2011-04-25
DE60313451D1 (de) 2007-06-06
ES2285120T3 (es) 2007-11-16
AU2003229060A1 (en) 2003-12-02

Similar Documents

Publication Publication Date Title
DE60313451D1 (de) Verfahren zur reinigung von adenovirus
ATE346861T1 (de) Verfahren zur reinigung und isolierung von viren, aus pflanzenquellen
ATE397092T1 (de) Methode zur direkten sequenzierung von nukleinsäuren
MX346184B (es) Resinas de amina-aldehido y sus usos en procesos de separacion.
BRPI0519361A2 (pt) resinas de amina-aldeÍdo modificadas e usos das mesmas em processos de separaÇço
DE60230788D1 (de) Isolierung und aufreinigung von nukleinsäuren
ATE497830T1 (de) Vorrichtung und verfahren zur reinigung von flüssigkeiten
BRPI0713566A2 (pt) Resinas de amina-aldeído modificadas e seus usos nos processos de separação
ATE248911T1 (de) Magnetische partikel zur reinigung von nukleinsäuren
HUP0200103A2 (hu) Eljárás vírus-inaktivált humán gamma-globulin G előállítására
DE60132094D1 (de) Verfahren zur Herstellung von gereinigten Partikeln
DE69904986D1 (de) Methode zur Abtrennung und Wiedergewinnung von Polyethylenglykol und Siliziumkarbid-Schleifmittel zum Zwecke ihrer Wiederverwendung
WO2007014244A3 (en) Method of purifying recombinant human antithrombin to enhance the viral and prion safety profile
SE8402861L (sv) Rening av biologiskt material
DE68928889D1 (de) Enzymatisches Reinigungsverfahren
DE602004030681D1 (de) Verfahren und vorrichtung zur reinigung von luft und wasser
GB0107634D0 (en) Nucleic acid purification
ATE354418T1 (de) Verwendung eines clathratmodifizierers zur forderung des durchgangs von proteinen bei nanofiltration
ATE389619T1 (de) Verfahren zur behandlung von industrieabwasserenthaltende organische schadstoffe
HUP0101995A2 (hu) Eljárás biológiai eredetű, szilárd anyagokat tartalmazó, vizes áramok kezelésére
ATE258606T1 (de) Verfahren zum nachweis von fehlpaarungen oder mutationen in nukleinsäuren
DE69223140T2 (de) Verfahren zur Reinigung von Quarzsand und anderen Materialien
DE69601777D1 (de) Verfahren zur Entfernung von Titan- oder Vanadiumalkoxid aus flüssigen Kohlenwasserstoffmischungen
ATE389627T1 (de) Kontinuierliches verfahren zur rückgewinnung von aceton aus einem abfallstrom der acetonreinigung